2023 年年报问询函回复的核查意见 关于上海谊众药业股份有限公司 容诚会计师事务所（特殊普通合伙） 容诚专字[2024]200Z0336 号 中国·北京 容诚会计师事务所(特殊普通合伙) 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 外经贸大厦 15 层 / 922-926 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 容诚会计师事务所（特殊普通合伙） 关于上海谊众药业股份有限公司 2023 年年报问询函回复的核查意见 容诚专字[2024]200Z0336 号 上海证券交易所： 根据贵所于 2024 年 5 月 23 日出具的《关于上海谊众药业股份有限公司 2023 年年度报告的信息披露监管问询函》(上证科创公函【2024】0119 号)（以下简 称"问询函"）的要求，容诚会计师事务所（特殊普通合伙）（以下简称"我 们"）作为上海谊众药业股份有限公司（以下简称"上海谊众"或"公司"） 2023 年度的年报审计机构，对问询函中 ...

http://roadshow.sseinfo.com/） 证券代码：688091 证券简称：上海谊众 公告编号：2024-021 上海谊众药业股份有限公司关于 召开 2023 年度暨 2024 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2024 年 06 月 5 日(星期三)下午 14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址： 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 06 月 05 日下午 14:00-15:00 （二） 会议召开地点：上海证券交易所"上证路演中心"网络平台（网址： http://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心网络文字互动 三、 参加人员 会议召开方式：上证路演中心网络文字互动 投资者可于 2024 年 05 月 29 日(星期三)至 06 月 4 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 i ...

证券代码：688091 证券简称：上海谊众 公告编号：2024-020 上海谊众药业股份有限公司 2023 年年度权益 分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 新增无限售条件流 | 现金红利发放日 | | --- | --- | --- | --- | | | | 通股份上市日 | | | 2024/5/16 | 2024/5/17 | 2024/5/17 | 2024/5/17 | 一、 通过分配、转增股本方案的股东大会届次和日期 本次利润分配及转增股本方案经公司 2024 年 4 月 29 日的 2023 年年度股东大 会审议通过。 二、 分配、转增股本方案 1. 发放年度：2023 年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 三、 相关日期 | 股权登记日 | 除权（息）日 | 新增无限售条件流 | 现金红利发放日 | ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 68,702,991.41, representing a decrease of 25.65% compared to the same period last year[27]. - The net profit attributable to shareholders for Q1 2024 was CNY 29,178,031.68, down 46.97% year-on-year[27]. - Basic and diluted earnings per share for Q1 2024 were both CNY 0.18, reflecting a decline of 52.63% year-on-year[27]. - The net profit for Q1 2024 was CNY 29,178,031.68, a decrease of 47% compared to CNY 55,025,022.44 in Q1 2023[48]. - Total operating revenue for Q1 2024 was ¥68,702,991.41, a decrease from ¥92,399,635.15 in Q1 2023, representing a decline of approximately 25.7%[61]. Cash Flow and Investments - The net cash flow from operating activities for Q1 2024 was CNY 28,877,820.51, a decrease of 3.21% compared to the previous year[27]. - The company reported cash inflows from investment activities totaling CNY 327,424,747.27, with cash outflows of CNY 311,815,478.90, resulting in a net cash flow from investment activities of CNY 15,609,268.37[21]. - The cash and cash equivalents at the end of Q1 2024 amounted to CNY 963,178,159.26, an increase from CNY 758,691,049.55 at the end of Q1 2023[21]. - Cash and cash equivalents amounted to ¥974,245,738.25, an increase from ¥914,763,371.24 at the end of the previous year[43]. Research and Development - Research and development expenses increased significantly as the company intensified its efforts in product promotion and development, impacting overall profitability[15]. - Total R&D investment reached ¥5,595,803.86, representing an increase of 114.99% year-over-year[36]. - R&D investment accounted for 8.14% of operating revenue, up by 5.32 percentage points from the previous year[36]. - R&D expenses rose to CNY 5,595,803.86, up from CNY 2,602,773.90, primarily due to increased clinical research for new indications of paclitaxel[55]. Assets and Liabilities - The total assets of the company as of Q1 2024 were CNY 1,615,717,426.60, compared to CNY 1,573,359,475.20 in the previous year[20]. - The company’s total liabilities increased to CNY 112,467,670.48 from CNY 103,983,754.93 year-on-year[20]. - The total liabilities increased to CNY 116,809,890.76 from CNY 108,522,872.33, indicating a growth in financial obligations[47]. - The total equity attributable to shareholders reached CNY 1,498,907,535.84, up from CNY 1,464,836,602.87, showing a positive trend in shareholder equity[47]. - Deferred income tax liabilities decreased slightly to CNY 2,987,582.53 from CNY 3,069,450.00, indicating a minor improvement in tax obligations[47]. Sales and Market Strategy - The company experienced a significant decline in sales volume of its core product, paclitaxel micelles, due to policy impacts affecting core customers[15]. - The company is focusing on expanding its product promotion efforts nationwide despite challenges in hospital access for core products[39]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[55]. Operating Costs - Total operating costs increased to CNY 36,997,180.69 from CNY 26,736,137.15, reflecting a significant rise in sales expenses[47]. Other Income - Other income for the period included government subsidies amounting to CNY 361,654.21, contributing positively to the financial results[53].

上海谊众药业股份有限公司 2023年年度股东大会会议资料 上海谊众药业股份有限公司 2023年年度股东大会会议资料 上海谊众 688091 二〇二四年四月 1 上海谊众药业股份有限公司 2023年年度股东大会会议资料 2 上海谊众药业股份有限公司 2023年年度股东大会会议资料 | 附件：上海谊众药业股份有限公司 | 2023 年度董事会工作报告 | 26 | | --- | --- | --- | | 附件：上海谊众药业股份有限公司 | 2023 年度监事会工作报告 | 32 | | 附件：上海谊众药业股份有限公司 | 2023 年度财务决算报告 | 35 | | 附件：上海谊众药业股份有限公司 | 2024 年度财务预算报告 | 41 | | 附件：上海谊众药业股份有限公司董事会议事规则 | | 42 | | 附件：上海谊众药业股份有限公司独立董事工作制度 | | 50 | | 附件：上海谊众药业股份有限公司关联交易管理制度 | | 62 | 3 上海谊众药业股份有限公司 2023年年度股东大会会议资料 上海谊众药业股份有限公司 上海谊众药业股份有限公司 2023年年度股东大会会议资料目录 | 上海谊众药 ...

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 161,553,919.38 for the year 2023, with a cash dividend of RMB 3.1 per 10 shares, totaling RMB 49,065,808.00, which represents 30.37% of the net profit [4]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2023, representing a 15% increase compared to the previous year [16]. - The total operating revenue for 2023 reached ¥360,253,871.23, representing a 52.68% increase compared to ¥235,957,004.22 in 2022 [23]. - The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, increased by 56.70% to ¥161,065,688.52 from ¥102,786,775.90 in the previous year [25]. - The basic earnings per share for 2023 was ¥1.02, a 3.03% increase from ¥0.99 in 2022 [24]. - The weighted average return on equity rose to 11.78%, an increase of 0.32 percentage points from 11.46% in 2022 [24]. - The gross margin for the year was reported at 45%, a slight increase from 43% in the previous year [16]. - The net profit attributable to shareholders was 161.55 million yuan, up 13.09% from 142.85 million yuan in the same period last year [35]. - The company achieved operating revenue of ¥360,253,871.23, a 52.68% increase from ¥235,957,004.22 in the same period last year [136]. User Growth and Market Expansion - The number of new users increased by 25% year-over-year, reaching 500,000 active users by the end of 2023 [16]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025 [16]. - A new product line is set to launch in Q3 2024, which is expected to contribute an additional 200 million RMB in revenue [16]. Research and Development - The company has allocated 100 million RMB for research and development in 2024, focusing on innovative drug delivery systems [16]. - Ongoing research and development efforts include expanding the indications for injectable paclitaxel micelles and developing new drugs targeting non-small cell lung cancer [38]. - The company has established a nanocarrier drug delivery system (NDDS) R&D platform to enhance drug precision, effectiveness, and safety [66]. - The company aims to enhance its profitability and sustainable development through effective R&D and market strategies, benefiting both investors and patients [37]. - The company has reported a significant increase in R&D expenses, rising 183.26% to ¥22,450,751.95 due to expanded clinical trials [138]. Clinical Trials and Product Development - The company is currently in the Phase II clinical trials for its new targeted therapy, with preliminary results indicating a 60% objective response rate (ORR) [16]. - The clinical practice data for injectable paclitaxel polymer micelles was selected for the 2023 ASCO Annual Meeting, showing an overall objective response rate (ORR) of 84.4% and a disease control rate (DCR) of 100% in a study of 45 patients [40]. - The company has initiated Phase III clinical trials for the injectable paclitaxel polymer micelle targeting breast cancer, with patient enrollment currently ongoing [173]. - The Phase II exploratory clinical studies for pancreatic cancer and esophageal squamous cell carcinoma have been largely completed, with plans to submit applications for Phase III clinical studies to the National Medical Products Administration in 2024 [101]. Production Capacity and Supply Chain - The company is advancing its production capacity expansion project, with a new production line receiving the drug production license in October 2023, ensuring future market supply [41]. - The company aims to accelerate the construction of a project to produce 5 million units of paclitaxel micelle injection annually, enhancing production capacity to meet future market demand [73]. - The company has established two production lines for paclitaxel micelle lyophilized powder injection, both of which have received the necessary production licenses and can commence commercial production activities [72][73]. Market Trends and Industry Insights - The global pharmaceutical market size is projected to grow from $1.2988 trillion in 2020 to $1.7114 trillion by 2025, with a compound annual growth rate (CAGR) of 5.7% [77]. - China's pharmaceutical market is expected to reach ¥2.2873 trillion by 2025, with a CAGR of 9.6%, surpassing the global growth rate [78]. - The global oncology drug market is forecasted to grow from $150.3 billion in 2020 to $304.8 billion by 2025, with a CAGR of 15.2% [81]. - The Chinese oncology drug market reached ¥197.5 billion in 2020, with a projected growth to ¥416.2 billion by 2025, reflecting a CAGR of 12.1% [81]. Governance and Compliance - The company emphasizes a scientific and standardized approach to R&D project management to support technological advancement and new product development [68]. - The governance structure has been strengthened, with five board meetings and five supervisory meetings held during the reporting period, ensuring compliance with legal regulations [195]. - The company is dedicated to maintaining high standards of information disclosure, ensuring transparency and fairness to protect the interests of all shareholders [195]. - The company confirmed that there are no significant differences in governance compared to regulations set by the China Securities Regulatory Commission [196]. Financial Risks and Challenges - The company faced risks related to uncertain timing for inclusion in the national medical insurance directory, affecting price competitiveness [132]. - The company is exposed to risks from regulatory changes in the highly regulated pharmaceutical industry, which could impact operations [134]. - The operating cash flow decreased by 21.87% to ¥86,554,073.66 compared to the previous year [137].

上海谊众药业股份有限公司董事会审计委员会 对 2023 年度会计师事务所履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》及《上海谊众药业股份有限公司章 程》等规定和要求，上海谊众药业股份有限公司（以下简称"公司"）董事会审 计委员会对会计师事务所 2023 年度履行监督职责的情况如下： （二）续聘会计师事务所履行的程序 公司于 2023 年 2 月 27 召开了第一届董事会审计委员会第一次会议、第一届 董事会第十八次会议，2023 年 4 月 3 日召开了公司 2022 年年度股东大会，审议 通过了《关于聘请容诚会计师事务所（特殊普通合伙）为公司 2023 年度审计机 构的议案》，同意聘请容诚会计师事务所（特殊普通合伙）为公司 2023 年度审 计机构，聘期一年。 公司董事会审计委员会对容诚会计师事务所（特殊普通合伙）的专业资格、 服务经验、诚信情况、审计团队的组成等进行了充分了解和审查，认为其具有 开展相关审计业务的专业资格，具备为公司提供客观、公正的 ...

上海谊众药业股份有限公司及全资子公司 使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海谊众药业股份有限公司（以下简称"公司"或"上海谊众"）于 2024 年 4 月 3 日召开了第二届董事会第四次会议、第二届监事会第四次会议，审议通过了 《关于公司及子公司使用闲置自有资金进行现金管理的议案》。同意公司及全资 子公司在确保不影响正常经营及风险可控的前提下，使用额度不超过人民币 130,000 万元的闲置自有资金开展现金管理业务，投资于安全性高、流动性好的 理财产品或结构化存款，自公司董事会审议通过之日起 12 个月内有效。在前述 额度及期限范围内，资金可以循环滚动使用。公司授权总经理在额度内办理具体 操作事宜。 现金管理金额：公司及子公司使用额度不超过 130,000 万元的暂时闲置 自有资金进行现金管理。在额度及期限范围内，资金可以循环滚动使 用。 现金管理期限：自公司董事会审议通过之日起 12 个月内有效。 履行的审议程序：2024 年 4 月 3 公司召开第二届董 ...

国金证券股份有限公司 关于上海谊众药业股份有限公司 2023 年度募集资金存放与使用情况的核查意见 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为上海谊众药 业股份有限公司（以下简称"上海谊众"或"公司"）首次公开发行股票并在科创板上 市的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》《科创板上市公司持 续监管办法（试行）》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的 监管要求》《上海证券交易所科创板股票上市规则》以及《上海证券交易所上市公司自 律监管指引第 11 号——持续督导》等有关规定，对上海谊众 2023 年度募集资金的存 放和使用情况进行了核查，具体情况如下： 一、首次公开发行股票募集资金的基本情况 （一）实际募集资金金额、资金到账情况 经中国证券监督管理委员会于 2021 年 8 月 3 日发布的《关于同意上海谊众药业股 份有限公司首次公开发行股票注册的批复》（证监许可[2021]2595 号）同意，公司向社 会公众公开发行人民币普通股（A 股）股票 2,645.00 万股，每股面值 1 元，发行价格 为每股人民币 38.10 元，募集资金总额为人民币 10 ...

公司代码：688091 公司简称：上海谊众 上海谊众药业股份有限公司 2023 年度内部控制评价报告 上海谊众药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了 评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责 组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内 容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外，由于情况的变化可 ...